IDH2 and neoplasm: This corresponds with the clinical observation that IDH mutations are present in approximately 70-80% of slower growing LGGs but only 10% of rapidly dividing glioblastomas and suggests a direct link between metabolic reprogramming and tumor growth rate (Hartmann et al., 2009; Kim et al., 2010; Turkalp et al., 2014; Louis et al., 2016).